TAPAS血管内封闭导管紫杉醇浸润与紫杉醇药物涂层球囊治疗股腘动脉狭窄的对比  

Paclitaxel infiltration using TAPAS intravascular closed catheter versus paclitaxel drug-coated balloon for the treatment of femoropopliteal artery stenosis:a comparison study

作　　者：王翔 郭建明[1] 崔世军[1] 齐立行[1] 郭连瑞[1] 谷涌泉[1] WANG Xiang;GUO Jianming;CUI Shijun;QI Lixing;GUO Lianrui;GU Yongquan(Department of Vascular Surgery,Xuanwu Hospital of Capital Medical University,Beijing 100053,China)

机构地区：[1]首都医科大学宣武医院血管外科,北京100053

出　　处：《介入放射学杂志》2023年第6期542-548,共7页Journal of Interventional Radiology

摘　　要：目的评价利用TAPAS血管内封闭导管的紫杉醇浸润在股腘动脉狭窄(FPAS)治疗中的应用价值。方法设置紫杉醇涂层DCB组(组1)和TAPAS导管组(组2)。对2017年6月至2020年6月在首都医科大学宣武医院接受介入治疗的一批患者进行回顾性队列研究。随访终点事件为术后2年或出现不良事件。首要观察指标为患者/患肢一期通畅率和不良事件发生率。结果共有73例患者符合入选标准。组1(n=55)、组2(n=18)间术前人口学、临床特点及术中造影诊断、预处理比较差异无统计学意义(均P>0.05)。截至随访终点,组1、组2患者/患肢间累积临床获益率(67.2%比88.9%)、一期通畅率(70.7%比77.8%)、非死亡不良事件率(18.3%比16.7%)、全因死亡率(3.6%比0%)比较差异无统计学意义(均P>0.05)。结论对于FPAS患者,利用TAPAS血管内封闭导管的紫杉醇浸润能在术后2年内持续达到与紫杉醇DCB同等的治疗效果。Objective To assess the application value of paclitaxel infiltration using TAPAS intravascular closed catheter in treating femoropopliteal artery stenosis(FPAS).Methods The paclitaxel drug-coated balloon(DCB)group(group A)and TAPAS catheter group(group B)were set up.A retrospective cohort study was conducted on a batch of patients who underwent endovascular interventions in Xuanwu Hospital of Capital Medical University of China between June 2017 and June 2020.Two years after interventional treatment or at the time when adverse event occurred was designated as the follow-up endpoint.The main observational indicators were the primary patency and the incidence of adverse events of the patients/affected limbs.Results A total of 73 patients(55 in group A and 18 in group B)met the inclusion criteria.There were no statistically significant differences in the preoperative demographic and clinical features,the intraoperative angiographic diagnosis,and the pre-treatment measures between the two groups(all P>0.05).As of the end of follow-up period,no statistically significant differences in the cumulative clinical benefit rate(67.2%vs 88.9%),primary patency rate(70.7%vs 77.8%),incidence of non-fatal adverse events(18.3%vs 16.7%),and all-cause mortality(3.6%vs 0%)existed between the two groups(all P>0.05).Conclusion For patients with FPAS,paclitaxel infiltration using TAPAS intravascular closed catheter carries the same curative effect as paclitaxel DCB within two years after treatment.

关 键 词：股腘动脉狭窄 紫杉醇 浸润 药物涂层球囊 

分 类 号：R543.5[医药卫生—心血管疾病]